When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase stock, like in AngioDynamics, Inc.'s (NASDAQ:ANGO) instance, it's good news for shareholders.

While insider transactions are not the most important thing when it comes to long-term investing, we do think it is perfectly logical to keep tabs on what insiders are doing.

View our latest analysis for AngioDynamics

The Last 12 Months Of Insider Transactions At AngioDynamics

Over the last year, we can see that the biggest insider purchase was by CEO, President & Director James Clemmer for US$121k worth of shares, at about US$6.03 per share. We do like to see buying, but this purchase was made at well below the current price of US$10.33. Because it occurred at a lower valuation, it doesn't tell us much about whether insiders might find today's price attractive.

Over the last year, we can see that insiders have bought 32.57k shares worth US$203k. But they sold 4.06k shares for US$50k. In the last twelve months there was more buying than selling by AngioDynamics insiders. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

AngioDynamics is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.

AngioDynamics Insiders Are Selling The Stock

Over the last three months, we've seen a bit of insider selling at AngioDynamics. Senior Vice President of Regulatory Affairs Warren Nighan divested only US$50k worth of shares in that time. Neither the lack of buying nor the presence of selling is heartening. But the volume sold is so low that it really doesn't bother us.

Does AngioDynamics Boast High Insider Ownership?

For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 3.4% of AngioDynamics shares, worth about US$14m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

So What Does This Data Suggest About AngioDynamics Insiders?

We did not see any insider buying in the last three months, but we did see selling. But the sales were small, so we're not concerned. But insiders have shown more of an appetite for the stock, over the last year. Insiders own shares in AngioDynamics and we see no evidence to suggest they are worried about the future. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. For example - AngioDynamics has 1 warning sign we think you should be aware of.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.